J. Douglass

Characterisation of an OCS-dependent severe asthma population treated with mepolizumab

H. Ortega, S. Wenzel, C. Prazma, 2014, Thorax.

Immunotherapy in asthma

F. Thien, R. O'hehir, J. Douglass, 1997, Thorax.

Myopathy in severe asthma.

M. Weinmann, G. Bowes, M. Horne, 1992, The American review of respiratory disease.

Induction of T ‘regulatory’ cells by standardized house dust mite immunotherapy: an increase in CD4+CD25+ interleukin‐10+ T cells expressing peripheral tissue trafficking markers

F. Thien, J. Rolland, L. Gardner, 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Short‐term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis

J. Morton, P. Eng, J. Douglass, 1996, Pediatric pulmonology.

Effect of Omalizumab on Exacerbations and Glucocorticoid Use in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis

W. Calhoun, J. Elborn, R. Agarwal, 2022, A31. REAL WORLD ASTHMA TREATMENT OUTCOMES, BIOMARKER STUDIES, PHENOTYPING, AND SEVERITY ASSESSMENTS.

Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient

J. Douglass, A. Voskamp, A. Wei, 2009, Allergy.

Changing practice: no need to stop ACE inhibition for venom immunotherapy

C. Slade, J. Douglass, Jo A Douglass, 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.